Filing Flows › Biolargo (BLGO) › Q1 2025
Biolargo (BLGO) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
Biolargo (BLGO) reported revenue of $3.3M for the first quarter 2025 (Q1 2025), -31% from a year earlier and -11% from the quarter before. Operating margin was -57.0%, net loss $1.9M (58.8% of revenue).
Biolargo, Q1 2025: revenue $3.3M (-31% year over year), operating margin -57.0%, net loss $1.9M, operating cash flow −$1.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.3M | -11% | -31% |
| Operating profit | −$1.9M | — | — |
| Net earnings | −$1.9M | — | — |
| Operating cash flow | −$1.8M | — | — |
What changed
Revenue was $3.3M in Q1 2025, down 31% year over year and down 11% from the previous quarter. Product was the largest line at 86% of revenue. Product lost $1.8M year over year (down 39%), 119% of the total change.
Gross margin was 45.5%, down 1.7 points from a year earlier. Operating costs exceeded revenue by $1.9M, an operating margin of -57.0%. Operating expenses grew 11% against a revenue fall of 31%. The fastest-growing cost line was SG&A (+13%). The quarter ended with a net loss of $1.9M, wider than the previous quarter's $1.7M loss. Minority interests bore $766K of it: to shareholders the quarter was a loss of $1.2M.
Operating cash flow was −$1.8M. Non-cash charges added back $42K of depreciation and $615K of share-based compensation. Working capital and other items used $566K.
Questions
What was Biolargo's revenue in the first quarter 2025?
Biolargo (BLGO) reported revenue of $3.3M for the first quarter 2025 (Q1 2025), -31% from a year earlier and -11% from the quarter before.
Was Biolargo profitable in the first quarter 2025?
Operating loss was $1.9M (-57.0% of revenue) and net loss $1.9M.
Source: Biolargo 10-Q on SEC EDGAR.